BridgeBio's Calcilytix Sees POC For Encaleret And Options To Discuss With FDA
Company Presents Early Phase II Data At ENDO
Calcilytix chief medical officer Jonathan Fox talked to Scrip about the development plans for encaleret for the rare form of hypoparathyroidism.
You may also be interested in...
Since raising $135m in 2017 to address rare, monogenic diseases, BridgeBio has launched or purchased 17 companies and built a pipeline of 30-plus candidates. Scrip checked in as the company nears commercialization.
In an interview, oncology development exec Peter Adamson reiterated the company’s view that THOR-707 is best-in-class, but more data are needed to see where its efficacy stands amid the IL-2 herd.
Together with a similar delay for AbbVie’s Rinvoq, the delays appear to stem from a study that raised concerns about the class. But the potential sales impact is less clear.